Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Cutaneous leishmaniasis treatment and therapeutic outcomes in special populations: A collaborative retrospective study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      Background: Treatment guidance for children and older adult patients affected by cutaneous leishmaniasis (CL) is unclear due to limited representation of these groups in clinical trials.
      Methods: We conducted a collaborative retrospective study to describe the effectiveness and safety of antileishmanial treatments in children ≤ 10 and adults ≥ 60 years of age, treated between 2014 and 2018 in ten CL referral centers in Latin America.
      Results: 2,037 clinical records were assessed for eligibility. Of them, the main reason for non-inclusion was lack of data on treatment follow-up and therapeutic response (182/242, 75% of children and 179/468, 38% of adults). Data on 1,325 eligible CL patients (736 children and 589 older adults) were analyzed. In both age groups, disease presentation was mild, with a median number of lesions of one (IQR: 1-2) and median lesion diameter of less than 3 cm. Less than 50% of the patients had data for two or more follow-up visits post-treatment (being only 28% in pediatric patients). Systemic antimonials were the most common monotherapy regimen in both age groups (590/736, 80.2% of children and 308/589, 52.3% of older adults) with overall cure rates of 54.6% (95% CI: 50.5-58.6%) and 68.2% (95% CI: 62.6-73.4%), respectively. Other treatments used include miltefosine, amphotericin B, intralesional antimonials, and pentamidine. Adverse reactions related to the main treatment were experienced in 11.9% (86/722) of children versus 38.4% (206/537) of older adults. Most adverse reactions were of mild intensity.
      Conclusion: Our findings support the need for greater availability and use of alternatives to systemic antimonials, particularly local therapies, and development of strategies to improve patient follow-up across the region, with special attention to pediatric populations.
      Competing Interests: The authors have declared that no competing interests exist.
      (Copyright: © 2023 Castro et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
    • References:
      Am J Trop Med Hyg. 2019 Feb;100(2):306-310. (PMID: 30628567)
      Acta Trop. 2011 May;118(2):87-96. (PMID: 21420925)
      Trans R Soc Trop Med Hyg. 2020 Jan 6;114(1):1-6. (PMID: 31703122)
      BMJ. 2007 Oct 20;335(7624):806-8. (PMID: 17947786)
      Am J Trop Med Hyg. 2012 Mar;86(3):426-33. (PMID: 22403312)
      Clin Infect Dis. 1993 Mar;16(3):417-25. (PMID: 8384011)
      PLoS One. 2017 May 30;12(5):e0178592. (PMID: 28558061)
      J Infect Dis. 2014 Jul 1;210(1):146-53. (PMID: 24443541)
      Am J Trop Med Hyg. 2001 Mar-Apr;64(3-4):187-93. (PMID: 11442216)
      Ann Trop Med Parasitol. 2001 Jun;95(4):331-6. (PMID: 11454242)
      BMC Infect Dis. 2022 Mar 28;22(1):302. (PMID: 35351012)
      J Infect Dis. 2007 Feb 15;195(4):602-8. (PMID: 17230422)
      PLoS One. 2017 Sep 19;12(9):e0184777. (PMID: 28926630)
      Antimicrob Agents Chemother. 2017 Feb 23;61(3):. (PMID: 27956421)
      Clin Infect Dis. 2019 Apr 24;68(9):1530-1538. (PMID: 30188978)
      Lancet. 1987 Jul 4;2(8549):13-6. (PMID: 2885505)
      Am J Trop Med Hyg. 2001 Nov;65(5):456-65. (PMID: 11716098)
      Ann Trop Med Parasitol. 2006 Jun;100(4):307-14. (PMID: 16762111)
      J Am Geriatr Soc. 2010 Mar;58(3):614-6. (PMID: 20398135)
      J Antimicrob Chemother. 2020 Nov 1;75(11):3260-3268. (PMID: 32780098)
      PLoS Negl Trop Dis. 2018 Dec 14;12(12):e0006986. (PMID: 30550538)
      Ann Intern Med. 1997 Feb 1;126(3):232-6. (PMID: 9027276)
      PLoS Negl Trop Dis. 2017 Apr 5;11(4):e0005515. (PMID: 28379954)
      Wkly Epidemiol Rec. 2002 Nov 1;77(44):365-70. (PMID: 12428426)
      Mem Inst Oswaldo Cruz. 2017 Dec;112(12):838-843. (PMID: 29211245)
      Mem Inst Oswaldo Cruz. 2016 Aug;111(8):512-6. (PMID: 27508321)
      Trop Med Int Health. 2018 Sep;23(9):936-942. (PMID: 29924907)
      Rev Soc Bras Med Trop. 2018 Nov-Dec;51(6):837-842. (PMID: 30517540)
      Trans R Soc Trop Med Hyg. 2009 Jul;103(7):703-6. (PMID: 19059616)
      Am J Trop Med Hyg. 2015 Jun;92(6):1173-7. (PMID: 25918209)
      Mem Inst Oswaldo Cruz. 2001 Feb;96(2):159-62. (PMID: 11285490)
      Am J Trop Med Hyg. 2013 Aug;89(2):359-64. (PMID: 23798581)
      PLoS Negl Trop Dis. 2013;7(3):e2130. (PMID: 23556016)
      Am J Trop Med Hyg. 2010 Jul;83(1):97-101. (PMID: 20595484)
      PLoS Negl Trop Dis. 2010 Dec 21;4(12):e912. (PMID: 21200420)
      Antimicrob Agents Chemother. 2012 Jul;56(7):3864-72. (PMID: 22585212)
      Rev Soc Bras Med Trop. 2006 Jan-Feb;39(1):22-6. (PMID: 16501761)
      Am J Trop Med Hyg. 2017 Nov;97(5):1503-1507. (PMID: 28820714)
    • Grant Information:
      MR/R010161/1 United Kingdom MRC_ Medical Research Council
    • Accession Number:
      0 (Antiprotozoal Agents)
      673LC5J4LQ (Pentamidine)
    • Publication Date:
      Date Created: 20230123 Date Completed: 20230206 Latest Revision: 20230315
    • Publication Date:
      20240105
    • Accession Number:
      PMC9894540
    • Accession Number:
      10.1371/journal.pntd.0011029
    • Accession Number:
      36689465